Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts

Medical Mycology
Eva PericoliniAnna Vecchiarelli

Abstract

A previous paper demonstrated that indinavir affects the virulence of Cryptococcus neoformans, thereby rendering the fungus more susceptible to killing by natural effector cells. This study demonstrates that inoculation of immunosuppressed mice with C. neoformans previously exposed to indinavir, in comparison to untreated C. neoformans, results in: (i) a more pronounced secretion of interleukin-12 by splenic dendritic cells; (ii) reduction of CD14 and Fc gammaRs expression on splenic dendritic cells, and upregulation of CD86 and CD40 molecules; (iii) enhancement of interferon-y and interleukin-2 production by splenic T cells and increase of their proliferation in response to fungal antigens; and (iv) survival from an otherwise lethal challenge, correlated with a drastic decrease in colony forming units from brain and liver. In conclusion, these data indicate that indinavir interaction with C. neoformans could be beneficial because of its direct influence on fungal virulence and blunting of the deleterious effects exerted by C. neoformans on host immune response. Thus, indinavir could be crucial in addressing the outcome of cryptococcosis in immunocompromised hosts.

References

Jun 1, 1992·Current Opinion in Immunology·R de Waal MalefytJ E de Vries
Jun 20, 1996·The New England Journal of Medicine·R Migliacci, P Gresele
Sep 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D W NotermansJ M Lange
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Aug 28, 1998·Research in Immunology·G B Huffnagle, M F Lipscomb
Feb 2, 1999·The Journal of Experimental Medicine·R Maldonado-LópezM Moser
Feb 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·B PulendranC R Maliszewski
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M S SaagW E Dismukes
Jul 6, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·K KawakamiA Saito
Jan 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ralph Marvin Steinman, Michel C Nussenzweig
Mar 27, 2002·Nature Reviews. Immunology·Ken Shortman, Yong-Jun Liu
Jun 29, 2002·Current Opinion in Immunology·Karolina Palucka, Jacques Banchereau
Sep 2, 2003·Nature Reviews. Immunology·Yvette van Kooyk, Teunis B H Geijtenbeek
Oct 3, 2003·International Journal of Antimicrobial Agents·Roberto ManfrediFrancesco Chiodo
Dec 21, 2004·The Journal of Infectious Diseases·Claudia MonariAnna Vecchiarelli

❮ Previous
Next ❯

Citations

Apr 16, 2011·The Journal of Antimicrobial Chemotherapy·Josep Guarro
Jan 1, 2008·Core Evidence·Susan L Davis, Jose A Vazquez
Jan 10, 2016·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Raimunda Sâmia Nogueira BrilhanteJosé Júlio Costa Sidrim
Oct 2, 2007·The Journal of Infection·Elio CenciAnna Vecchiarelli
Sep 28, 2018·PLoS Neglected Tropical Diseases·Daniele Gonçalves CastilhoWagner Luiz Batista
Feb 7, 2008·Journal of Leukocyte Biology·Eva PericoliniAnna Vecchiarelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.